^
2ms
The DNA sensor AIM2 mediates psoriasiform inflammation by inducing type 3 immunity. (PubMed, JCI Insight)
We found elevated levels of mitochondrial DNA in patients with psoriasis, along with high expression of AIM2 in both the human psoriatic epidermis and a mouse model of psoriasis induced by topical imiquimod (IMQ) application. Finally, the genetic absence of inflammasome components downstream AIM2, ASC, and caspase-1 alleviated IMQ-induced skin inflammation. Collectively, our data show that AIM2 is involved in developing psoriasis through its canonical activation.
Journal
|
AIM2 (Absent In Melanoma 2) • IL17A (Interleukin 17A) • IL23A (Interleukin 23 Subunit Alpha) • CASP1 (Caspase 1)
|
Zyclara (imiquimod) • Vesimune (imiquimod intravesical)
5ms
A Window of Opportunity Phase I Study of UGN-201 in Patients With Bladder Cancer Undergoing Radical Cystectomy Protocol #: 2021-0630 (clinicaltrials.gov)
P1, N=10, Suspended, M.D. Anderson Cancer Center | Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Aug 2024 --> Aug 2025
Trial completion date • Trial primary completion date
|
Vesimune (imiquimod intravesical)
7ms
A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) (clinicaltrials.gov)
P1, N=60, Recruiting, UroGen Pharma Ltd. | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
Trial completion date • Trial primary completion date • Combination therapy
|
gemcitabine • zalifrelimab (UGN-301) • Vesimune (imiquimod intravesical)
11ms
Trial suspension
|
Vesimune (imiquimod intravesical)
4years
TLR3/TAK1 signalling regulates rhinovirus-induced interleukin-33 in bronchial smooth muscle cells. (PubMed, ERJ Open Res)
BSMCs from healthy and severe and non-severe asthmatic patients were infected with RV1B or stimulated with the PRR agonists poly(I:C) (Toll-like receptor 3 (TLR3)), imiquimod (TLR7) and poly(I:C)/LyoVec (retinoic acid-inducible gene 1 (RIG-I)/melanoma differentiation-associated protein 5 (MDA5)). RV-induced IL-33 expression was mainly regulated by TLR3 and downstream via TAK1. These signalling molecules represent potential therapeutic targets for treating asthma exacerbations.
Journal
|
CXCL8 (Chemokine (C-X-C motif) ligand 8) • IL17A (Interleukin 17A)
|
Zyclara (imiquimod) • Vesimune (imiquimod intravesical)
4years
Red-kerneled rice proanthocyanidin inhibits arachidonate 5-lipoxygenase and decreases psoriasis-like skin inflammation. (PubMed, Arch Biochem Biophys)
In imiquimod-induced psoriasis-like mouse skin, topical application of the proanthocyanidin suppressed hyperplasia, decreased inflammatory cell infiltration, and down-regulated expression of the psoriasis-associated genes Il17a, Il22, S100a9, and Krt1. Red-kerneled rice proanthocyanidin inhibits 5-lipoxygenase, resulting in a decrease in leukotriene B production and psoriasis-like mouse skin inflammation. These results suggest that this proanthocyanidin may be therapeutically effective for treating leukotriene-related diseases.
Journal
|
S100A9 (S100 Calcium Binding Protein A9) • IL17A (Interleukin 17A)
|
S100A9 expression
|
Zyclara (imiquimod) • Vesimune (imiquimod intravesical)
4years
A dual and conflicting role for imiquimod in inflammation: a TLR7 agonist and a cAMP phosphodiesterase inhibitor. (PubMed, Biochem Pharmacol)
To conclude, our results indicate that the widely used inflammatory drug, imiquimod, is not only a TLR7 agonist, but also harbors a novel anti-inflammatory function as a PDE inhibitor. This off-target affects the desired therapeutic inflammatory activity of imiquimod and may be accountable for adverse side effects.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • TLR4 (Toll Like Receptor 4)
|
Zyclara (imiquimod) • Vesimune (imiquimod intravesical)
over4years
Lesional therapies for in-transit melanoma. (PubMed, J Surg Oncol)
IL-2 may be considered for the treatment of ITM with multiple or rapidly developing lesions where there would otherwise be significant morbidity with surgery, given pCR rates and toxicity.
Journal
|
IL2 (Interleukin 2)
|
Zyclara (imiquimod) • Vesimune (imiquimod intravesical)
over4years
[VIRTUAL] Cathelicidin LL-37 facilitates damage-associated molecular patterns to be bioactive substances by intermediating between scavenger receptors (SID 2020)
We incubated normal human epidermal keratinocyte (NHEKs) or human leukemia monocytic cell line THP-1 with synthetic dsRNA, dsDNA, High Mobility Group Box 1 (HMGB1), or Toll-like receptor 7 agonist imiquimod, and examined cytokine production. Since LL-37 is a biphasic and cationic peptide, these data suggested that LL-37 selectively interacts with scavenger receptors and intermediates between DAMPs and scavenger receptors to facilitate DAMPs signaling in epithelial cells and mononuclear cells. These data imply us that the blockage of the interaction among LL-37, DAMPs and scavenger receptors can be novel therapeutic targets of innate type skin inflammation.
IO biomarker
|
IL6 (Interleukin 6)
|
Zyclara (imiquimod) • Vesimune (imiquimod intravesical)
over4years
Linear basal cell nevus with a novel mosaic PTCH1 mutation. (PubMed, Exp Dermatol)
Given the young age of our patient and linear distribution of BCCs on non-sun exposed skin, our findings suggest segmental mosaicism. The patient was treated with topical 5% imiquimod with histologically confirmed clearance of BCCs in 2 months.
Journal
|
PTCH1 (Patched 1)
|
Zyclara (imiquimod) • Vesimune (imiquimod intravesical)
over4years
Successful Treatment of In-Transit Metastatic Melanoma in a Renal Transplant Patient With Combination T-VEC/Imiquimod Immunotherapy. (PubMed, J Immunother)
In solid organ transplant patients who lack surgical options and are not eligible for treatment with a BRAF inhibitor, and for whom treatment with checkpoint inhibitors present risk of organ rejection, T-VEC either alone or in combination with topical imiquimod should be considered for patients with locally advanced disease. This combination should be a consideration, with close observation, in patients with a history of organ transplantation and immunosuppression.
Clinical • Journal
|
BRAF (B-raf proto-oncogene)
|
Imlygic (talimogene laherparepvec) • Zyclara (imiquimod) • Vesimune (imiquimod intravesical)
over4years
Imiquimod and interferon-alpha augment monocyte-mediated astrocyte secretion of MCP-1, IL-6 and IP-10 in a human co-culture system. (PubMed, J Neuroimmunol)
Furthermore, TLR7-induced monocyte-derived IL-1β is critical for promoting the astrocyte response. Overall, this study provides a potential mechanism for TLR7-mediated neuroinflammation.
Preclinical • Journal
|
IL6 (Interleukin 6)
|
Zyclara (imiquimod) • Vesimune (imiquimod intravesical)
over4years
Combination of PEG-decorated black phosphorus nanosheets and immunoadjuvant for photoimmunotherapy of melanoma. (PubMed, J Mater Chem B)
Herein, we have reported a photothermal-immunotherapy of melanoma using pegylated black phosphorus nanosheets (BP-PEG NSs) and imiquimod (R837) as the photothermal conversion agent and the immunoadjuvant, respectively. In vivo antitumor studies in B16 tumor-bearing mice demonstrated that photoimmunotherapy showed the best tumor inhibition effects. Our study suggested that BP-PEG NS-based PTT primed with an immunoadjuvant can be used for synergistic photoimmunotherapy of melanomas.
Clinical • Journal
|
IL6 (Interleukin 6)
|
Zyclara (imiquimod) • Vesimune (imiquimod intravesical)
over4years
[VIRTUAL] Efficacy of imiquimod in the management of lentigo maligna. (ASCO 2020)
This randomized prospective study shows that imiquimod reduces the LM area (-50%) after one month of treatment. Reducing the surface of LM with imiquimod is not associated with a higher risk of intralesional excision (marge 5mm), with a significant esthetic result (less excised surface). Research Funding: French Hospital Clinical Research Program in Cancer
Clinical
|
IFNG (Interferon, gamma)
|
Zyclara (imiquimod) • Vesimune (imiquimod intravesical)
almost5years
A TLR7 agonist strengthens T and NK cell function during BRAF-targeted therapy in a preclinical melanoma model. (PubMed, Int J Cancer)
Their effector cell function could be restored by additional peritumoral treatment with the TLR7 agonist imiquimod, a clinically approved agent for nonmelanoma skin cancer. Indeed, resistance to BRAFi therapy was delayed and accompanied by high numbers of activated T and NK cells in tumors. Thus, combining BRAFi with an immune stimulating agent such as a TLR ligand could be a promising alternative approach for the treatment of melanoma.
Preclinical • Journal
|
BRAF (B-raf proto-oncogene) • PTEN (Phosphatase and tensin homolog)
|
Zyclara (imiquimod) • Vesimune (imiquimod intravesical)